Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
The Role of Immunohistochemistry in the Diagnosis and Prognosis of...
share announcement

The Role of Immunohistochemistry in the Diagnosis and Prognosis of Tumors: New Findings

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 2040

Special Issue Editors

Dr. Lorenzo Memeo

E-Mail Website
Guest Editor
Pathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, 95029 Catania, Italy
Interests: gastrointestinal tumors; endocrine tumors; urological tumors; breast tumors
Special Issues, Collections and Topics in MDPI journals
Dr. Cristina Colarossi

E-Mail Website
Guest Editor
Pathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, 95029 Viagrande, Italy
Interests: gastrointestinal tumors; hematological malignancies; gynecological tumors

Special Issue Information

Dear Colleagues,

Immunohistochemistry plays a crucial role in the diagnosis of neoplastic disease and a growing number of new antibodies are available to pathologist to increase the diagnostic accuracy. Moreover, oncologists need specific biomarker expression in order to select a specific target therapy. In addition, in recent years we have seen a progressive increase of molecular characterization of tumors, finalized to the selection of the best therapeutic options. Some antibodies reflect mutational status of the tumors and can be used to replace complex molecular analysis. Therefore, immunohistochemistry for its capillary distribution and for its quick turnaround time remains a key technique in the evaluation of prognostic markers and target therapy selection, either as a screening tool or as a stand-alone method.In this special issue we would like to collect experiences from pathologist and researches with new diagnostic antibodies (including new application for old antibodies), the role of immunohistochemistry as prognostic factors or as a therapy selection tool.Main focus of the special issue would be the evaluation of microsatellite instability, the molecular classification of gastrointestinal neoplasms but would include also all applications of immunohistochemistry.Submission is open to original research and review papers but uncommon and/or teaching case reports will also be considered.

Dr. Lorenzo Memeo
Dr. Cristina Colarossi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Immunohistochemistry
  • Diagnosis of tumors
  • Prognostic factors
  • Target therapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 4894 KiB  
Article
TOX Expression in Mycosis Fungoides and Sezary Syndrome
by Alessandro Pileri, Martina Cavicchi, Clara Bertuzzi, Simona Righi, Corrado Zengarini, Elena Sabattini, Giovanna Roncador and Claudio Agostinelli
Diagnostics 2022, 12(7), 1582; https://doi.org/10.3390/diagnostics12071582 - 29 Jun 2022
Cited by 2 | Viewed by 1529
Abstract
Mycosis fungoides (MF) and Sezary syndrome (SS) are the two most common type of cutaneous T-cell lymphoma (CTCL). Currently, no markers can be clearly related to prognosis or to differential diagnosis between early stages and inflammatory benign diseases (IBD). The thymocyte selection-associated high [...] Read more.
Mycosis fungoides (MF) and Sezary syndrome (SS) are the two most common type of cutaneous T-cell lymphoma (CTCL). Currently, no markers can be clearly related to prognosis or to differential diagnosis between early stages and inflammatory benign diseases (IBD). The thymocyte selection-associated high mobility group box factor (TOX), has been proposed as a possible marker in differential diagnosis between early CTCL stages and IBD. Recently TOX has been related to prognosis. We aimed to investigate whether TOX may be a diagnostic or prognostic marker. MF and SS biopsies between 2010 and 2020 were retrieved. New tissues slides were stained with an anti-TOX antibody, (Clone NAN448B). On each slide, 5 fields were examined at high magnification (400×), to evaluate the percentage of marker-positivity in a quantitative way. Thirty-six patients (12 females and 24 males) and 48 biopsies were collected. Nine patients had multiple biopsies. TOX expression in MF/SS cases showed an increase from early to advanced phases. TOX was not regarded as a prognostic marker due to the absence of significant changes by comparing early MF cases with reactive conditions. TOX statistical significance increased in patients alive with disease and in those dead of disease (p = 0.013 and = 0.0005, respectively) as compared with patients in complete remission. Our results show that TOX should be regarded more as a prognostic than a diagnostic marker. Full article
(This article belongs to the Special Issue The Role of Immunohistochemistry in the Diagnosis and Prognosis of Tumors: New Findings)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop